Market capitalization | GBP8.55b |
Enterprise Value | GBP10.99b |
P/E (TTM) P/E ratio | 35.33 |
EV/FCF (TTM) EV/FCF | 45.70 |
EV/Sales (TTM) EV/Sales | 2.45 |
P/S ratio (TTM) P/S ratio | 1.91 |
P/B ratio (TTM) P/B ratio | 2.08 |
Dividend yield | 3.83% |
Last dividend (FY23) | GBP0.38 |
As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.
20 Analysts have issued a Smith & Nephew forecast:
20 Analysts have issued a Smith & Nephew forecast:
Jun '24 |
+/-
%
|
||
Revenue | 4,482 4,482 |
1%
1%
|
|
Gross Profit | 3,094 3,094 |
1%
1%
|
|
EBITDA | 1,185 1,185 |
11%
11%
|
EBIT (Operating Income) EBIT | 661 661 |
17%
17%
|
Net Profit | 242 242 |
35%
35%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Deepak Nath |
Employees | 19,551 |
Founded | 1856 |
Website | www.smith-nephew.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.